Comparative Pharmacology
Head-to-head clinical analysis: CARDIOGEN 82 versus NEPHROSCAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARDIOGEN 82 versus NEPHROSCAN.
CARDIOGEN-82 vs NEPHROSCAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CardioGen-82 (rubidium Rb-82 generator) produces rubidium Rb-82, a positron-emitting radiotracer that is taken up by myocardial cells via the sodium-potassium ATPase pump, reflecting myocardial perfusion. Its distribution is proportional to blood flow, allowing PET imaging of myocardial perfusion defects.
Calcium trisodium pentetate (NEPHROSCAN) chelates gadolinium ions by forming a stable complex with the metal, thereby reducing the toxicity and enhancing elimination of gadolinium from the body. It acts as a decorporation agent for gadolinium.
Single intravenous dose of 0.3-0.6 mCi (11.1-22.2 MBq) followed by a 0.9% sodium chloride flush at 1-3 mL/sec.
1 to 5 mCi (37 to 185 MBq) as a single intravenous injection for renal imaging.
None Documented
None Documented
Terminal elimination half-life is 60–90 seconds (for the parent radionuclide Rb-82). Clinical context: Short half-life allows rapid repeat imaging; myocardial uptake is proportional to blood flow.
Terminal elimination half-life: 1.6 hours in normal renal function; prolonged to >20 hours in severe renal impairment (CrCl <30 mL/min).
Renal; >90% eliminated unchanged in urine within 24 hours. Fecal excretion is negligible.
Renal: 95% as unchanged drug via glomerular filtration; no biliary/fecal excretion.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical